newsroom

You are here

Home / newsroom

2011

December 08, 2011
Cylene First-in-Class Agents Show Promise in High Risk Blood Cancers at ASH Read more
October 12, 2011
Cylene Advances Breakthrough p53 Activator Toward the Clinic Read more
June 06, 2011
Cylene Presents Encouraging Clinical Data for Oral CK2 Inhibitor at ASCO Read more

2010

December 06, 2010
Cylene Selected to Present CK2 Inhibitor Multiple Myeloma Data At American Society of Hematology Meeting Read more
November 16, 2010
Cylene to Present Advances with Industry’s Only Clinical CK2 Inhibitor, CX-4945, at EORTC-NCI-AACR Read more
October 19, 2010
Horizon Discovery and Cylene Pharmaceuticals Collaborate in Rational Selection of Patients for Clinical Trials Read more
September 24, 2010
Cylene Initiates Phase I Trial in Multiple Myeloma with CX-4945 Inhibitor of CK2 and Closes Accompanying Financing Read more
September 08, 2010
Cylene to Report Recent Advances with First-in-class CK2 Inhibitor, CX-4945, at International CK2 Conference Read more

2009

May 19, 2009
Cylene to Announce New Data on its First-In-Class Oral CK2 Inhibitor against Cancer at BIO Conference Read more
April 17, 2009
Cylene to Present Advances in its Oral Inhibitor of CK2 at AACR Annual Meeting Read more
January 05, 2009
Cylene Pharmaceuticals Initiates Phase I Trial with CX-4945 – Breakthrough First-in Class Inhibitor of CK2 Read more
January 01, 2009
Cylene Pharmaceuticals Promotes John K.C. Lim, Pharm.D. and David M. Ryckman, Ph.D. to Senior Vice Presidents Read more

2008

March 14, 2008
Cylene Pharmaceuticals Promotes Claire S. Padgett to Vice President of Clinical Operations Read more
January 28, 2008
Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology Read more

2007

July 10, 2007
Cylene Pharmaceuticals Appoints David M. Ryckman, Ph.D. as Vice President of Manufacturing and Pharmaceutical Operations Read more
January 23, 2007
Cylene Pharmaceuticals Closes $44 Million Series C Financing Read more